Cargando…

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes

Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. SLC3A2 was assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Ansari, Rokaya, Craze, Madeleine L., Diez-Rodriguez, Maria, Nolan, Christopher C., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931111/ https://www.ncbi.nlm.nih.gov/pubmed/29545595 http://dx.doi.org/10.1038/s41416-018-0038-5

Ejemplares similares

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer
por: Ansari, Rokaya El, et al.
Publicado: (2019)

Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer
por: Morotti, Matteo, et al.
Publicado: (2020)

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
por: Craze, Madeleine L, et al.
Publicado: (2018)

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
por: Joseph, Chitra, et al.
Publicado: (2018)

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation
por: Bouthelier, Antonio, et al.
Publicado: (2022)

Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2)
por: Fogelstrand, Per, et al.
Publicado: (2009)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival
por: Pu, Xuan, et al.
Publicado: (2016)

Role of SLC4 and SLC26 solute carriers during oxidative stress
por: Remigante, Alessia, et al.
Publicado: (2022)

Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients
por: Mirza, Sameer, et al.
Publicado: (2013)

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS)
por: Toss, Michael S., et al.
Publicado: (2018)

Slc11 Synapomorphy: A Conserved 3D Framework Articulating Carrier Conformation Switch
por: Cellier, Mathieu F. M.
Publicado: (2023)

2-Hydroxyoleic acid-inserted liposomes as a multifunctional carrier of anticancer drugs
por: Jang, Eun-Ji, et al.
Publicado: (2017)

Trospium Chloride Transport by Mouse Drug Carriers of the Slc22 and Slc47 Families
por: Gorecki, Matthias, et al.
Publicado: (2020)

Human solute carrier SLC6A14 is the β-alanine carrier
por: Anderson, Catriona M H, et al.
Publicado: (2008)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

SLC3A2 and SLC7A2 Mediate the Exogenous Putrescine-Induced Adipocyte Differentiation
por: Eom, Jin, et al.
Publicado: (2022)

Evidence for genetic susceptibility to the alcohol dependence syndrome from the thiamine transporter 2 gene solute carrier SLC19A3
por: Quadri, Giorgia, et al.
Publicado: (2014)

CYP2S1 and CYP2W1 expression is associated with patient survival in breast cancer
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

The SLC25 Mitochondrial Carrier Family: Structure and Mechanism
por: Ruprecht, Jonathan J., et al.
Publicado: (2020)

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer
por: Alshareeda, A T, et al.
Publicado: (2015)

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products
por: Cheng, Xiamin, et al.
Publicado: (2022)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer
por: Kariri, Yousif, et al.
Publicado: (2022)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

Analysis and update of the human solute carrier (SLC) gene superfamily
por: He, Lei, et al.
Publicado: (2009)

Mammalian Solute Carrier (SLC)-like transporters of Legionella pneumophila
por: Best, Ashley, et al.
Publicado: (2018)

Mitochondrial SLC25 Carriers: Novel Targets for Cancer Therapy
por: Rochette, Luc, et al.
Publicado: (2020)

The genetic landscape of the human solute carrier (SLC) transporter superfamily
por: Schaller, Lena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nnofq4c2i7aqkug99cproe9cku